| Literature DB >> 32998416 |
Erika Aparecida Silveira1,2, Marianne Oliveira Falco2, Annelisa Silva E Alves de Carvalho Santos2, Matias Noll3, Cesar de Oliveira1.
Abstract
Antiretroviral therapy (ART) increases the risk of cardiometabolic diseases in people living with HIV/AIDS (PLWHA). However, there is a lack of evidence regarding the effectiveness of a nutritional intervention on several cardiometabolic parameters in this population. Therefore, this study aimed to evaluate the effectiveness of two nutritional interventions on several cardiometabolic parameters in PLWHA treated with ART. A parallel randomized clinical trial was performed with PLWHA treated with ART. The participants (n = 88) were divided into two intervention groups: (1) nutritional counseling (n = 44) and (2) individualized dietary prescription (n = 44). The follow-up period was 30 weeks. A reduction in low-density lipoprotein (LDL) was the primary outcome. Secondary outcome variables were reductions in total cholesterol (TC), triglycerides (TG), fasting plasma glucose (FPG), systolic and diastolic blood pressures (SBP and DBP, respectively), waist circumference (WC), body mass index (BMI), and increases in high-density lipoproteins (HDL). A multiple linear regression was used to analyze the effectiveness of the interventions, adjusted for sociodemographic, lifestyle, and clinical characteristics. Sixty-two PLWHA completed the trial (nutritional counseling, n = 32; individualized dietary prescription, n = 30). At follow-up, we observed in the nutritional counseling group significant reductions in SBP (p = 0.036) and DBP (p = 0.001). Significant reductions in FPG (p = 0.008) and DBP (p = 0.023) were found in the individualized dietary prescription group. In the fully adjusted models, significant reductions in LDL, SBP, DBP, and BMI were found in the individualized dietary prescription group. In conclusion, the two investigated nutritional interventions were effective in reducing some cardiometabolic risk factors in PLWHA. However, after adjustments for covariates, the individualized dietary prescription showed significant reductions in the primary outcome and, also, in more cardiometabolic risk factors than the nutritional counseling.Entities:
Keywords: AIDS; HIV; antiretroviral therapy; cardiometabolic risk factors; dietary intervention; dyslipidemia; individualized dietary prescription; nutritional counseling
Mesh:
Substances:
Year: 2020 PMID: 32998416 PMCID: PMC7601880 DOI: 10.3390/nu12102970
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flowchart of entry in clinical trial and follow-up of the participants in groups-nutritional counseling group and diet group. Completers’ analysis.
Sociodemographic, clinical, and cardiometabolic data at baseline for people living with HIV/AIDS (PLWHA) according to their allocated groups.
| Variables | Nutritional Counseling Group | Diet Group | ||
|---|---|---|---|---|
|
| 0.861 * | |||
| Male | 42 (67.74) | 22 (52.38) | 20 (47.62) | |
| Female | 20 (32.26) | 10 (50.00) | 10 (50.00) | |
|
| 0.821 † | |||
| ≤29 | 11 (17.74) | 6 (54.55) | 5 (45.45) | |
| 30–39 | 21 (33.87) | 12 (57.14) | 9 (42.86) | |
| 40–49 | 21 (33.87) | 9 (42.86) | 12 (57.14) | |
| 50 or above | 9 (14.52) | 5 (55.56) | 4 (44.44) | |
|
| 0.806 * | |||
| White | 32 (51.61) | 17 (53.13) | 15 (46.88) | |
| Brown/black | 30 (48.39) | 15 (50.00) | 15 (50.00) | |
|
| 0.355 † | |||
| Single | 32 (51.61) | 17 (53.13) | 15 (46.88) | |
| Married | 14 (22.58) | 5 (35.71) | 9 (64.29) | |
| Widower/ | 16 (25.81) | 10 (62.50) | 6 (37.50) | |
|
| 0.602 † | |||
| 1st (poorest) | 13 (20.97) | 5 (38.46) | 8 (61.54) | |
| 2nd | 15 (24.19) | 9 (60.00) | 6 (40.00) | |
| 3rd | 13 (20.97) | 8 (61.54) | 5 (38.46) | |
| 4th (richest) | 21 (33.87) | 10 (47.62) | 11 (52.38) | |
|
| 0.526 † | |||
| ≤4 years | 8 (12.90) | 4 (50.00) | 4 (50.00) | |
| 5–8 years | 17 (27.42) | 8 (47.06) | 9 (52.94) | |
| 9–11 years | 20 (32.26) | 13 (65.00) | 7 (35.00) | |
| >11 years | 17 (27.42) | 7 (41.18) | 10 (58.82) | |
|
| 0.980 * | |||
| Yes | 12 (19.35) | 6 (50.00) | 6 (50.00) | |
| No | 38 (61.29) | 20 (52.63) | 18 (47.37) | |
| Ex-smoker | 12 (19.35) | 6 (50.00) | 6 (50.00) | |
|
| 0.450 * | |||
| Yes | 32 (51.61) | 18 (56.25) | 14 (43.75) | |
| No | 30 (48.39) | 14 (46.67) | 16 (53.33) | |
|
| 0.065 * | |||
| Yes | 36 (58.06) | 15 (41.67) | 21 (58.33) | |
| No | 26 (41.94) | 17 (65.38) | 9 (34.62) | |
|
| 0.230 † | |||
| Yes | 2 (3.23) | - | 2 (100.00) | |
| No | 60 (96.77) | 32 (53.33) | 28 (46.67) | |
|
| 0.110 † | |||
| <50 copies/mL | 47 (79.66) | 22 (46.81) | 25 (53.19) | |
| ≥50 copies/mL | 12 (20.34) | 9 (75.00) | 3 (25.00) | |
|
| 0.135 † | |||
| ≤0.5 years | 16 (29.63) | 12 (75.00) | 4 (25.00) | |
| 0.5–1 year | 5 (9.26) | 4 (80.00) | 1 (20.00) | |
| 1–3 years | 15 (27.78) | 9 (60.00) | 6 (40.00) | |
| >3 years | 18 (33.33) | 6 (33.33) | 12 (66.67) | |
|
| 0.204 * | |||
| Yes | 43 (71.67) | 20 (46.51) | 23 (53.49) | |
| No | 17 (28.33) | 11 (64.71) | 6 (35.29) | |
|
| 0.050 † | |||
| Yes | 18 (30.00) | 13 (72.22) | 5 (27.78) | |
| No | 42 (70.00) | 18 (42.86) | 24 (57.14) | |
|
|
| |||
|
| 62 | 84.65 ± 9.39 | 88.02 ± 10.03 | 0.177 ‡ |
| BMI (kg/m2) | 62 | 23.81 ± 3.55 | 25.05 ± 3.90 | 0.197 ‡ |
| Total cholesterol mg/dL | 62 | 178.34 ± 47.59 | 197.80 ± 43.62 | 0.099 ‡ |
| LDL-C (mg/dL) | 62 | 103.72 ± 37.79 | 119.10 ± 38.78 | 0.122 ‡ |
| HDL-C (mg/dL) | 62 | 40.72 ±10.13 | 44.00 ± 12.26 | 0.287 ‡ |
| Triglyceride (mg/dL) | 62 | 167.88 ± 71.64 | 187.97 ± 90.33 | 0.464 § |
| Fasting plasma glucose (mg/dL) | 62 | 83.53 ± 7.73 | 89.80 ± 7.96 | 0.003 § |
| Systolic pressure (mmHg) | 62 | 117.53 ± 13.17 | 119.40 ± 13.77 | 0.587 ‡ |
| Diastolic pressure (mmHg) | 62 | 82.13 ± 8.43 | 80.57 ± 9.78 | 0.503 ‡ |
Values are n (%) or average ± SD. * Values obtained by Pearson X2 test. † Values obtained by Fischer Exact Test. ‡ Values obtained by Student’s t-test for independent variables. § Values obtained by Mann–Whitney U-test for independent non-parametric variables. PLWHA: People living with HIV/AIDS; ART: antiretroviral therapy; BMI: body mass index; HDL-C: high-density lipoprotein; LDL-C: low-density lipoprotein; NNRTI: non-nucleoside reverse transcriptase inhibitors; SD: standard deviation.
Cardiometabolic variables: comparison of baseline data with the end of follow-up for each group of the randomized clinical trial.
| Variables | Nutritional Counseling Group | Diet Group | ||||||
|---|---|---|---|---|---|---|---|---|
|
| Baseline | Follow-up |
| Baseline | Follow-up | |||
| Dyslipidemia | 32 | 31 (96.88) | 21 (65.63) | 0.002 † | 30 | 29 (96.67) | 22 (73.33) | 0.039 † |
| Isolated hypercholesterolemia a | 32 | 4 (12.50) | 2 (6.25) | 0.500 † | 28 | 3 (10.70) | 3 (10.70) | 1.000 † |
| Hypertriglyceridemia | 32 | 18 (56.25) | 11 (34.38) | 0.092 † | 30 | 20 (66.67) | 12 (40.00) | 0.032 † |
| Average ± SD | Average ± SD | |||||||
| Total cholesterol (mg/dL) | 32 | 178.34 ± 47.59 | 174.00 ± 43.88 | 0.423 | 30 | 197.80 ± 43.62 | 188.40 ± 37.32 | 0.099 |
| LDL (mg/dL) # | 32 | 103.72 ± 37.79 | 100.84 ± 34.35 | 0.479 | 28 | 119.57 ± 39.41 | 109.54 ± 40.81 | 0.143 |
| HDL (mg/dL) | 32 | 40.72 ± 10.13 | 43.56 ± 10.06 | 0.095 | 30 | 44.00 ± 12.26 | 45.80 ± 14.31 | 0.266 ‡ |
| Triglyceride (mg/dL) | 32 | 167.88 ± 71.64 | 146.44 ± 69.21 | 0.112 | 30 | 187.97 ± 90.33 | 160.43 ± 91.28 | 0.089 ‡ |
| Fasting plasma glucose (mg/dL) | 32 | 83.53 ± 7.73 | 81.91 ± 8.37 | 0.275 | 30 | 90.14 ± 7.88 | 86.38 ± 9.72 | 0.008 ‡ |
| Systolic pressure (mmHg) | 32 | 117.53 ± 13.17 | 113.34 ± 10.94 | 0.036 | 30 | 119.40 ± 13.77 | 115.03 ± 9.39 | 0.066 |
| Diastolic pressure (mmHg) | 32 | 82.13 ± 8.43 | 76.94 ± 7.73 | 0.0009 | 30 | 80.57 ± 9.78 | 77.20 ± 7.10 | 0.023 |
| Waist circumference (cm) | 32 | 84.65 ± 9.39 | 84.42 ± 9.38 | 0.774 | 26 § | 88.77 ± 10.53 | 87.03 ± 9.99 | 0.068 |
| BMI (kg/m2) | 32 | 23.81 ± 3.55 | 24.03 ± 3.72 | 0.617 | 26 § | 25.14 ± 4.12 | 24.78 ± 4.09 | 0.151 |
Values are n (%) or average ± SD. a PLWHA without other associated dyslipidemias. * Values obtained by Student’s t-test for paired variables. † Values obtained by McNemar’s test for paired and categorical variables. ‡ Values obtained by Wilcoxon test for non-parametric paired variables. § Four PLWHA did not follow up to anthropometry. BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SD: standard deviation. # The two missing individuals in the LDL group occurred due to missing blood assays in the laboratory.
Effectiveness of each nutritional treatment on cardiometabolic variables.
| Variables |
| Nutritional Counseling Group * | Diet Group * |
|---|---|---|---|
| Total cholesterol (mg/dL) | 62 | −4.34 ± 30.25 | −9.40 ± 30.22 |
| LDL (mg/dL) | 60 | −2.88 ± 22.70 | −10.04 ± 35.18 |
| HDL (mg/dL) | 62 | 2.84 ± 9.34 | 1.80 ± 8.22 |
| Triglyceride (mg/dL) | 58 | −21.44 ± 74.16 | −27.53 ± 80.43 |
| Fasting plasma Glucose(mg/dL) | 58 | −1.63 ± 8.27 | −3.76 ± 8.35 |
| Systolic pressure (mmHg) | 62 | −4.19 ± 10.80 | −4.37 ± 12.52 |
| Diastolic pressure (mmHg) | 62 | −5.19 ± 7.95 | −3.37 ± 7.61 |
| Waist circumference (cm) | 58 | −0.28 ± 4.52 | −1.74 ± 4.65 |
| BMI (kg/m²) | 58 | 0.22 ± 2.41 | −0.36 ± 1.22 |
* Values refer to the average difference of the results between the baseline and the end of follow-up. Values are average ± standard deviation (SD). Negative values represent a decrease and positive values represent an increase. BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD: standard deviation.
Multiple linear regression of the effectiveness of each nutritional treatment on cardiometabolic outcomes.
| Variables | Nutritional Counseling Group | Diet Group | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| A | Adjusted β * | Effectiveness | R² | α | Adjusted β * | Effectiveness † | R² | |||
| Total cholesterol (mg/dL) | - | - | - | - | - | - | - | - | - | - |
| LDL | - | - | - | - | - | 2.74 | −27.50 | −24.76 | 0.158 | 0.036 |
| HDL | 8.34 | −12.94 | −4.6 | 0.206 | 0.013 | - | - | - | - | - |
| Triglyceride (mg/dL) | −47.89 | 60.46 | 12.57 | 0.169 | 0.019 | - | - | - | - | - |
| Fasting plasma glucose (mg/dL) | - | - | - | - | - | - | - | - | - | - |
| Systolic pressure (mmHg) | −8.75 | 8.48 | −0.27 | 0.163 | 0.024 | −0.45 | −11.75 | −12.2 | 0.202 | 0.013 |
| Diastolic pressure (mmHg) | - | - | - | - | - | −17.68 | 7.83 | −9.85 | 0.154 | 0.035 |
| Waist circumference (cm) | −1.83 | 3.31 | 1.48 | 0.138 | 0.036 | - | - | - | ||
| BMI (kg/m²) | - | - | - | −1.18 | 1.15 | −0.03 | 0.238 | 0.035 | ||
The values were obtained by a multiple lineal regression analysis. * Values were adjusted by sex, age, income, smoking, alcohol consumption, inactivity, family history of cardiovascular disease, ART usage time, protease inhibitor, non-nucleoside reverse transcriptase inhibitors/and nucleoside reverse transcriptase inhibitors. Blank spaces mean that none of the adjusted variables modified the effectiveness in cardiometabolic outcomes. † Effectiveness: difference among the values of each outcome variable between the baseline and the end of the follow-up. BMI, body mass index; ART, antiretroviral therapy; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PI, protease inhibitor.